Abstract: Compositions and methods for the nasal administration of drugs with reduced nasal irritation are disclosed.

Abstract: Compounds of formula (I), wherein A represents CH.dbd.CH; Q represents pyrazine having substituents R.sup.6 and R.sup.7 ; R.sup.1 represents H or C.sub.1-6 alkyl; R.sup.2 represents H, C.sub.1-6 alkyl, C.sub.3-6 alkenyl, C.sub.3-6 alkynyl, C.sub.3-6 cycloalkyl or NH.sub.2 CH.sub.2 CO--; R.sup.3 represents H, C.sub.1-6 alkyl, C.sub.3-6 alkenyl or C.sub.3-6 alkynyl; R.sup.4 and R.sup.5 independently represent H, OH, C.sub.1-6 alkoxy, C.sub.1-6 alkyl, halogen, trifluoromethyl or NR.sup.8 R.sup.9 ; R.sup.6 and R.sup.7 independently represent H, OH, C.sub.1-6 alkoxy, C.sub.1-6 alkyl, halogen, trifluoromethyl, C.sub.1-6 hydroxyalkyl, amidino, CONH.sub.2 or NR.sup.8 R.sup.9 ; in addition, R.sup.6 and R.sup.7 may independently represent O when substituted on N; R.sup.8 and R.sup.9 independently represent H or C.sub.1-6 alkyl; and pharmaceutically acceptable derivatives thereof. The compounds are useful as pharmaceuticals, in particular in the treatment of neurological disorders.

Abstract: Compounds of formula I, ##STR1## wherein M is Met, DMet, MeMet, MetO, Ahx, DAhx, MeAhx, Leu, MeLeu, Pro, Ile, MeIle, Ala or Lys, G is Gly, DAla, Pro, Ala, .beta.Ala or Sar; W is Trp, MeTrp, Ala or Nal; X is Met, MeMet, MetO, Ahx, MeAhx, Leu, MeLeu, Pro, Ile, MeIle, Ala, Phe, Lys or Lys(R.sup.8); J is Asp, DAsp, MeAsp, Asp(OBn), Ala or MeDAsp; F.sup.1 is (S)--NH, (R)--NH, (S)--R.sup.1 N or (R)--R.sup.2 N; F.sup.2 is H, Cl, I, Br, F, NO.sub.2, NH.sub.2, R.sup.3 or OR.sup.4 ; Z is NH.sub.2, NHR.sup.5 or NR.sup.5 R.sup.6 ; R.sup.1, R.sup.2, R.sup.3, R.sup.5 and R.sup.6 are alkyl C.sub.1-6 ; R.sup.4 is H or alkyl C.sub.1-4 ; R.sup. is OH or OSO.sub.3 H; and pharmaceutically acceptable derivatives thereof; are useful as therapeutic agents, in particular in the inhibition of feeding.

Abstract: Compounds of formula (I), ##STR1## in which R.sub.1 and R.sub.2, which may be the same or different, represent hydrogen, C.sub.1-6 alkyl, R.sub.3 and R.sub.4 independently represent one or more radicals selected from hydrogen, OH, NH.sub.2, NO.sub.2, halogen, C.sub.1-6 alkyl or C.sub.1-6 alkoxy and n is an integer from 1-2 inclusive, and pharmaceutically acceptable derivatives thereof are useful as pharmaceuticals; in particular, they possess N-methyl-(d)-aspartate(NMDA) blocking properties and are useful in the treatment and/or prevention of neurodegenerative conditions.

Abstract: (S)-.alpha.-phenyl-2-pyridineethanamine, and its pharmaceutically acceptable derivatives, are useful in the treatment of neurodegenerative disorders, and exhibit linear pharmacokinetics.

Abstract: There is provided a method of treatment of neurological disorders, such as epilepsy, stroke and cerebral ischaemia, which comprises the administration of a compound of Formula I: ##STR1## wherein, Ar.sub.1 and Ar.sub.2, which may be the same or different, independently represent phenyl or phenyl substituted by one or more of amino, nitro, halogen, hydroxy, C1 to 6 alkoxy, C1 to 6 alkyl or cyano;R.sub.1 represents hydrogen, C1 to 6 alkyl, C1 to 6 alkoxycarbonyl;R.sub.2 represents hydrogen or COCH.sub.2 NH.sub.2 ;R.sub.3 represents hydrogen or C1 to 6 alkyl;in addition, when R.sub.2 represents hydrogen either one or both of Ar.sub.1 and Ar.sub.2 may also represent 2-, 3- or 4-pyridinyl and R.sub.1 may also represent trihalomethyl;or a pharmaceutically acceptable salt thereof.Some of the compounds of formula I are novel, and these are also provided, together with pharmaceutical compositions containing the novel compounds.

Abstract: There is provided a nebulizing element suitable for nebulizing a liquid, comprising:a) oscillator means; andb) a cover sheet;the cover sheet being disposed between the oscillator means and the liquid to be nebulized in use; and having a metallic chemically inert layer which contacts the liquid to be nebulized in use, and a metallic energy transmission layer bonded thereto; characterized in that the metallic chemically inert layer and the metallic energy transmission layer are bonded to one another by a metallic bond. Nebulizer devices comprising such elements are also provided.

Abstract: Compounds are provided of the following general structure: ##STR1## wherein B is hydrogen or lower alkyl (C.sub.1 -C.sub.4), R.sub.1 is hydrogen or methyl, R.sub.2 is lower alkyl (C.sub.1 -C.sub.4), phenylmethyl or 2-(aminocarbonyl)ethyl, R.sub.3 is H or lower alkyl (C.sub.1 -C.sub.4) and where W and Q are independently selected from phenyl or 4-fluorophenyl. They are useful for providing sedative and antiepileptic activity.

Abstract: Compounds of the formula I, ##STR1## wherein R.sub.1, R.sub.2, R.sub.3 and R.sub.4 independently represent hydrogen, alkyl, phenyl or substituted phenyl with the proviso that two of R.sub.1, R.sub.2, R.sub.3 or R.sub.4 are phenyl or substituted phenyl and two of R.sub.1, R.sub.2, R.sub.3 or R.sub.4 are hydrogen or alkyl;m represents an integer from 1-2; andn represents an integer from 1-3;or a pharmaceutically acceptable salt thereof. The compounds are useful as pharmaceuticals, in particular, in the treatment of epilepsy.

Abstract: There is provided a method of treatment of neurological disorders, such as epilepsy, stroke and cerebral ischaemia, which comprises the administration of a compound of Formula I: ##STR1## wherein, Ar.sub.1 and Ar.sub.2, which may be the same or different, independently represent phenyl or phenyl substituted by one or more of amino, nitro, halogen, hydroxy, C1 to 6 alkoxy, C1 to 6 alkyl or cyano;R.sub.1 represents hydrogen, C1 to 6 alkyl, C1 to 6 alkoxycarbonyl;R.sub.2 represents hydrogen or COCH.sub.2 NH.sub.2 ;R.sub.3 represents hydrogen or C1 to 6 alkyl;in addition, when R.sub.2 represents hydrogen either one or both of Ar.sub.1 and Ar.sub.2 may also represent 2-, 3- or 4-pyridinyl and R.sub.1 may also represent trihalomethyl;or a pharmaceutically acceptable salt thereof.Some of the compounds of formula I are novel, and these are also provided, together with pharmaceutical compositions containing the novel compounds.

Abstract: There are described pharmaceutical compositions comprising aqueous solutions of 7 c l r - ,2,3,4-tetrahydro-2-methyl-3-2-methylphenyl)-4-oxo-6-quinazolinesulfonamid e. ethanol and a cosolvent selected from propylene glycol or polyethylene glycols suitable for parenteral administration to a patent suffering from refractory edema.

Abstract: Compounds of the formula I, ##STR1## in which: R.sub.1 represents hydrogen or C.sub.1-6 alkyl,R.sub.2 represents hydrogen, C.sub.1-6 alkyl, C.sub.3-6 alkenyl, C.sub.3-6 alkynyl or C.sub.3-6 cycloalkyl,R.sub.3 represents one or more radicals selected from hydrogen, hydroxy, C.sub.1-6 alkyl, C.sub.1-6 alkoxy, halogen, trifluoromethyl, amino, lower alkylamino or dilower alkylamino,R.sub.4 represents one or more radicals selected from hydrogen or C.sub.1-6 alkyl,A represents an alpha-amino acid acyl group or an alkoxycarbonyl group,and pharmaceutically acceptable salts thereof are useful as pharmaceuticals, in particular they possess N-methyl-(d)-aspartate (NMDA) blocking properties and are useful in the treatment and/or prevention of neurological disorders such as stroke, cerebral ischaemia, cerebral palsy, hypoglycaemia, epilepsy, Alzheimer's disease, Huntington's chorea, Olivo-ponto-cerebellar atrophy, perinatal asphyxia and anoxia.

Abstract: Compounds are provided of the following general structure: ##STR1## wherein R.sub.4 is lower alkyl (C.sub.1 -C.sub.4); R.sub.1 is hydrogen or methyl, R.sub.2 is hydrogen or methyl, R.sub.3 is lower alkyl (C.sub.1 -C.sub.6) or cyclopropyl, and where R.sub.5 and Q are independently selected from phenyl or 4-fluorophenyl. They are useful for providing sedative and antiepileptic activity.

Abstract: Novel peptides having sulfate ester groups and containing 6 to 9 amino acids; possessing feeding inhibition properties and capable of stimulating the contraction of the gallbladder. Also methods of treating and preventing obesity in which these novel peptides or other specified peptides can be used.

Abstract: Compounds of general formula I, ##STR1## wherein R.sup.1 represents hydrogen or alkyl C.sub.1-3,R.sup.2 represents hydrogen or alkyl C.sub.1-6,n and m are integers from 1 to 3, provided that n+m=4, andone of X and Y represents CH.sub.2 and the other represents CHR.sup.3, C.dbd.O, C.dbd.CHR.sup.4 or C.dbd.NR.sup.5, in whichR.sup.3, R.sup.4 and R.sup.5 are as defined in the specification,and their saltsare useful as pharmaceuticals, in particular as central muscarinic acetylcholine receptors. The compounds are therefore useful in the treatment of diseases such as presenile and senile dementia, Huntington's chorea, tardive dyskinesia, hyperkinesia, mania and Tourette Syndrome, and also as analgesic agents for use in the treatment of severe painful conditions such as rheumatism, arthritis, and terminal illness.

Abstract: Compounds of general formula I, ##STR1## wherein: A represents (CH.sub.2).sub.m optionally substituted by R.sub.3,B represents (CH.sub.2).sub.n optionally substituted by R.sub.4,R.sub.1 represents hydrogen, C.sub.1 -C.sub.6 alkyl, C.sub.1-6 alkenyl or C.sub.1-6 alkynyl,R.sub.2 represents hydrogen, C.sub.1 -C.sub.6 alkyl or COOR.sub.5, in which R.sub.5 represents C.sub.1 -C.sub.6 alkyl,R.sub.3 and R.sub.4 independently represent hydrogen or C.sub.1 -C.sub.6 alkyl,in addition, any two of R.sub.2, R.sub.3 and R.sub.4 may together form a C.sub.1-3 alkylene chain,n and m independently represent an integer from 1-3 inclusive,Y represents O or S,and pharmaceutically acceptable acid addition salts thereof are useful as pharmaceuticals, in particular as central muscarinic acetylcholine receptor agonists. The compounds are therefore useful in the treatment of diseases such as presenile and senile dementia, Huntington's chorea, tardive dyskinesia, hyperkinesia, mania and Tourette Syndrome.

Abstract: Compounds are provided of the following general structure: ##STR1## wherein A is 2-pyrrolidinyl, 2-piperidinyl or 4-thiazolidinyl and R and R.sub.1 are independently selected from hydrogen and methyl. They are useful for providing sedative and antiepileptic activity.

Abstract: Coatings for individual ion exchange resin particles comprised of (a) ethylcellulose and (b) corn oil or acetylated monoglycerides.

Abstract: 4-Dibenzocycloheptenyl, 4-dibenzocycloheptyl, and 4-dibenzoxepinylpiperidine compounds possessing antihistaminic activity.

Abstract: 7-[3-[(3,4-dihydroxyphenethyl)amino]-2-hydroxypropoxy]-flavone hydrobromide, and related flavonoids are disclosed to inhibit leukotrienes and 5-lipoxygenase; preferred compounds also inhibit rat anaphylaxis.